



# Définition du volume hypoxique dans les cancers bronchiques

## *Expérience RTEP6*


Thureau S, Gouel P, Piton N, Dujon A, Baste JM, Daniel L, Modzelewski R, Bohn P, Grégoire V, Vera P

Département Radiothérapie et Physique Médicale - Médecine Nucléaire


Centre Henri Becquerel & Quant.IF (EA4108 – FR CNRS 3638)

# Planning PET (selective nodal irradiation)


- Reduction of radiation fields
  - ✓ Possibility for boost
  - ✓ Decrease dose in oesophagus, normal lung and myocardium



Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study



# RTEP5 – Phase II of boost in NSCLC



25 non-inclusions


12 ineligibility regarding FDG<sub>1</sub> (**including 9 M+ [11%] on FDG<sub>1</sub>**)

8 bad procedures (inadapted induction CT, technical or logistic problems)


4 patient decision

1 investigator decision

24/34 (**70%**) patients with boost



# RTEP5 – Phase II of boost in NSCLC



# Analyse des traceurs à faible contraste


## Positif vs négatif

Global  $\kappa$ -Test for Visual Analysis of PET/CT Images for  
18 Nuclear Medicine Physicians at 18 Centers

$\kappa$	$^{18}\text{F}$ -FDG	$^{18}\text{F}$ -FMISO	$^{18}\text{F}$ -FLT
5 classes	0.59	0.43	0.44
2 classes	0.81	0.77	0.77




## Définition des volumes



# Analyse des traceurs à faible contraste

Sensitivity and Specificity of Different Methods of Volume Delineation



# Tumoural hypoxia and RT

- TEP/PET-Imidazolé

✓  $^{18}\text{F}$ -misonidazole

✓  $^{18}\text{F}$ -FAZA

✓  $^{18}\text{F}$ -FETA

✓  $^{18}\text{F}$ -FETNIM

✓  $^{18}\text{F}$ -EF1

✓  $^{18}\text{F}$ -EF3

✓  $^{18}\text{F}$ -EF5

✓  $^{124}\text{I}$ -IAZA

✓  $^{124}\text{I}$ -IAZG


✓  $^{124}\text{I}$ -IAZGP

✓  $^{18}\text{F}$ -FRP10

✓  $^{18}\text{F}$ -HX4

✓  $^{68}\text{Ga}$ -NOTA-NI

✓ ...




- TEP/PET-non-imidazolé

✓ Cu-ATSM

✓  $^{89}\text{Zr}$ -cG250-F(ab')<sub>2</sub>,  $^{124}\text{I}$ -cG250-F(ab')<sub>2</sub> (HIF-1 $\alpha$ , CA-IX)

# RTEP6. Etude comparative de l'hypoxie mesurée en TEP/TDM au F-miso et au FAZA chez les patients atteints d'un cancer broncho-pulmonaire non à petites cellules au moment du diagnostic : Corrélation avec l'immunohistochimie



# Méthodologie - Prospective

- ✓ Cancer histologiquement prouvé
- ✓ Fixation TEP- FDG positive
- ✓ Absence de traitement néoadjuvant (chimiothérapie, radiothérapie)
- ✓ Traitement chirurgical carcinologique
  - ✓ Lobectomie
  - ✓ Pneumonectomie



# Résultats préliminaires


## ✓ Population:

- ✓ 13 patients inclus – 10 patients analysés
- ✓ 8 hommes – 2 femmes
- ✓ Age moyen: 67 (+/- 7)


## ✓ Délais des examens:

- ✓ Délai FDG – Premier examen hypoxie : 5 jours (+/- 4,7)
- ✓ Délai FMISO – FAZA: 2,1 jours (+/- 2)
- ✓ Dernier examen hypoxie : 2,5 jours (+/- 3)

# Résultats préliminaires : SUV





	SUV max FAZA	SUV max FMISO	p
SUV	2.3	3.15	0.0048
SD	0.6	1.2	




	FAZA T/Aorte	FMISO T/Aorte	p
	1.95	2.34	0.07
SD	0.45	0.94	

# Résultats préliminaires : Volume




	Volume FAZA	Volume FMISO	p
Volume (cc)	4.14	6.54	0.18
SD	5	9.3	


	Volume FAZA/FDG	Volume FMISO/FDG	p
rapport	0.19	0.29	0.14
SD	0.07	0.22	









FDG




FMISO



FAZA











FMISO



FDG





FAZA




# Conclusion

- ✓ Résultats préliminaires
- ✓ Méthodologie rigoureuse avec
  - ✓ Délai entre examens faible
  - ✓ Patient sur plan dur
- ✓ Supériorité du FMISO versus FAZA
  - ✓ SUVmax
  - ✓ Rapport signal tumeur sur bruit de fond



# Perspectives

- ✓ Poursuite des inclusions
- ✓ Analyse des données TEP versus les données immuno-histochimiques
- ✓ HIF-1 $\alpha$ , CAIX, GLUT-1, LDH-5, MCT4
- ✓ Définition de nouvelles méthodes de segmentation



# Acknowledgement

- Research team
  - ✓ Dr S.Thureau
  - ✓ Mme I.Gardin
  - ✓ Pr S.Ruan
  - ✓ Pr B.Dubray
  - ✓ Dr P.Bohn
  - ✓ Mr S.Hapdey
  - ✓ Mr JF.Ménard
  - ✓ Mme C.Petitjean
  - ✓ Dr S.Becker
  - ✓ Dr A.Edet-Sanson
  - ✓ Pr C.Savoye-Collet
  - ✓ Dr M.Salaun
  - ✓ Pr L.Thiberville
  - ✓ Mr J.Lapuyade-Lahorgue
- Clinical research Unit
  - ✓ Mme D.Richard
  - ✓ Mr O.Rastelli, Mme L.Burel
  - ✓ Mr LF.Pepin
- Clinique du Cèdre
  - ✓ Dr Dujon
- CHU de Rouen
  - ✓ Dr JM. Baste
- MIRO Unit - Brussels
  - ✓ Pr V.Grégoire
  - ✓ Dr X.Geets
  - ✓ J.Lee
  - ✓ D.Labare